Physician profile
Brian S Wayne
NPI 1275641169
$12,693.49
in general payments reported to CMS, 2019-2025
26 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,045 · 2020: $858 · 2021: $1,403 · 2022: $1,964 · 2023: $1,904 · 2024: $2,161 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,978 · Education: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,977.95 |
| Education | $446.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,998.66 | 2019-2025 | |
| Abbvie INC. | $1,990.17 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $1,422.52 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,350.72 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,184.41 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Janssen Biotech, INC. | $1,128.71 | 2019-2025 | Tremfya |
| Amgen INC. | $855.54 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $766.24 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $436.64 | 2021-2025 | Bimzelx |
| Pfizer INC. | $345.67 | 2019-2025 | |
| Galderma Laboratories, L.P. | $281.89 | 2020-2025 | Nemluvio |
| Genzyme Corporation | $251.92 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $150.22 | 2024-2025 | Sotyktu |
| Dusa Pharmaceuticals, INC. | $109.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.14 | 2022-2024 | Spevigo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $86.12 | 2023-2024 | Opzelura |
| Celgene Corporation | $50.34 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.49 | 2019 | |
| Organon LLC | $34.98 | 2024-2025 | Vtama |
| Dermira, INC. | $24.41 | 2019 | |
| Janssen Scientific Affairs, LLC | $18.69 | 2022 | |
| Dermavant Sciences, INC. | $14.38 | 2024 | Vtama |
| Genentech USA, INC. | $13.42 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Mission Pharmacal Company | $12.49 | 2019 | |
| Prugen, INC. Pharmaceuticals | $7.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wayne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.